*Must be a SITC member to apply.
Designed for patients and caregivers, this interactive activity takes a closer look at the potential side effects of cancer immunotherapy. Based on the Patient Resource Guide, Understanding Cancer Immunotherapy 3rd Edition, this activity explains side effects that patients may experience while receiving cancer immunotherapy treatment and how to manage these side effects.
Check out the latest content on The Sentinel, SITC's official blog:
Ensure your patients are receiving all of their cancer care options. Register for an upcoming Advances in Cancer Immunotherapy™ (ACI) program for one of the following cities:
Jan. 19 in Atlanta, GA – Feb. 9 in Durham, NC – Feb. 24 in Charleston, SC – March 3 in Dallas, TX – March 24 in Buffalo, NY
Review SITC's coverage from National Harbor, Md. for the 32nd Annual Meeting, visit The Sentinel, SITC's official blog, to read scientific highlights, view daily photo galleries and much more.
"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group"
Projects of the 2017 SITC Sparkathon have been announced! Learn more about teams TimIOs and the METIOR Incubator, and see how you can support and become involved in the efforts of these talented young investigators.
SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*
*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.
In partnership with Medscape Oncology, SITC offers a robust online learning portal designed to provide clinical oncologists with free, CME-/CE-certified education in the immunotherapy field.
Explore resources and educational opportunities for cancer
patients and those who advocate for them.
Track the latest advancements and educational opportunities in
cancer immunotherapy and immunology.
Advance science, submit your
manuscript and monitor the global progress of cancer immunotherapy research.
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. But cytotoxic chemotherapy can also destroy actively proliferating ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita Axelrod, MD; Stephanie Bork, MSN, CRNP; Nathaniel R. Evans III, ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com